Biosimilar development and regulation in Japan

Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 4

Abstract

In Japan, biosimilars guidelines following the principles of the EU framework were established by Japan’s Ministry of Health, Labor and Welfare in March 2009. The guidelines cover the manufacturing process, characterization of quality attributes, and clinical and non-clinical studies for biosimilars. In this paper, the requirements for regulatory approval of biosimilars in Japan are outlined.

Authors and Affiliations

GaBI Journal Editor

Keywords

Related Articles

What to look forward to in GaBI Journal, 2013, Issue 2

The first of two Letters to the Editor is from Ms Gaspani and Ms Milani expressing their concerns about the lack of clear regulatory guidelines for approval of liposomal generic formulations. Liposomal products are only...

Commentary on the recommendations of the European Society for Organ Transplantation Advisory Committee on generic substitution of immunosuppressive drugs

In 2010, the Council of the European Society for Organ Transplantation formed an Advisory Committee to formulate recommendations on the use of generic drugs in solid organ transplant recipients. The initiative was taken...

Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency; influence and future directions

Dr Brian Godman reviews the paper by Markovic-Pekovic et al. regarding recent reforms in the Republic of Srpska. These include prescribing restrictions where concerns with the value of products and measures to obtain low...

IAPO launched the Patient-Centred Healthcare Indicators Review

In October 2012, the International Alliance of Patients’ Organizations (IAPO) launched its final Patient-Centred Healthcare Indicators Review and accompanying consultation report [1]. The review forms the initial stage o...

Alleviating concerns around generic antiepileptic medications

Epilepsy features the unpredictable onset of seizures that can be devastating to a patient’s quality of life. Fortunately there are medications available to control the onset of seizures. But because these have to be tak...

Download PDF file
  • EP ID EP354783
  • DOI 10.5639/gabij.2013.0204.055
  • Views 115
  • Downloads 0

How To Cite

GaBI Journal Editor (2013). Biosimilar development and regulation in Japan. Generics and Biosimilars Initiative Journal, 2(4), 207-208. https://europub.co.uk/articles/-A-354783